title: Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands.
abstract: A persistent infection with human papillomavirus (HPV) is a prerequisite for the development of cervical cancer. Clinical trials with HPV-vaccines have been very successful in preventing persistent HPV16/18 infections, the two most oncogenic HPV-genotypes. We assessed the introduction of universal HPV-vaccination for preadolescent girls in the Dutch National Immunization Programme. Long-term vaccine efficacy, the need and extent of a catch-up programme for young women, and the impact of vaccination on the cervical cancer screening programme are major unresolved issues. Preliminary conservative estimates (80% vaccine efficacy and no effects on the screening programme, transmission rate, non-cervical cancer incidence, and cross protection) predict an acceptable cost-effectiveness ratio for universal vaccination of preadolescent girls.
authors.affiliation: Laboratory for Infectious Diseases and Perinatal Screening, RIVM, Bilthoven, The Netherlands. hein.boot@rivm.nl
authors.forename: Hein J
authors.initials: HJ
authors.lastname: Boot
authors.forename: Iris
authors.initials: I
authors.lastname: Wallenburg
authors.forename: Hester E
authors.initials: HE
authors.lastname: de Melker
authors.forename: Marie-José M
authors.initials: MJ
authors.lastname: Mangen
authors.forename: Annette A M
authors.initials: AA
authors.lastname: Gerritsen
authors.forename: Nicoline A
authors.initials: NA
authors.lastname: van der Maas
authors.forename: Johannes
authors.initials: J
authors.lastname: Berkhof
authors.forename: Chris J L M
authors.initials: CJ
authors.lastname: Meijer
authors.forename: Tjeerd G
authors.initials: TG
authors.lastname: Kimman
mesh_terms: D017677:Age Distribution; D002648:Child; D003075:Coitus; D000075202:Contraindications; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D017589:Immunization Programs; D015994:Incidence; D009426:Netherlands / Q000453:epidemiology; D030361:Papillomavirus Infections / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage* / Q000191:economics / Q000276:immunology*; D011788:Quality of Life; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology
chemical_list: D053918:Papillomavirus Vaccines